Research programme: transdermal Parkinson's disease therapeutics - Corium International

Drug Profile

Research programme: transdermal Parkinson's disease therapeutics - Corium International

Alternative Names: Corplex ropinirole - Corium International; Pramipexole TDS - Corium International; Pramipexole transdermal - Corium International; Ropinirole TDS - Corium International; Ropinirole transdermal - Corium International

Latest Information Update: 17 Feb 2015

Price : $50

At a glance

  • Originator Corium International
  • Class Amines; Benzothiazoles; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 01 Dec 2014 Preclinical trials in Parkinson's disease in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top